The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses

Segment 10 of the double-stranded RNA (dsRNA) genome from African horse sickness virus serotype 4 (AHSV-4) was cloned and sequenced. The sequence of the coding region showed a total length of 667 bp. Nucleotide comparisons showed a 95% sequence similarity between serotypes 4 and 9, and 76% between serotypes 4 and 3. cDNA clones containing the coding region were cloned in the vector pET3xb and expressed in Escherichia coli. The NS3 gene product was synthesised at very high level as an insoluble fusion protein. The recombinant protein was used in a differential ELISA to distinguish horses that were infected with AHSV-4 or vaccinated with live-modified virus from those vaccinated with a purified inactivated vaccine. The results obtained indicate that recombinant NS3 can indeed differentiate between infected and vaccinated animals implying that this recombinant could be developed as a diagnostic reagent, and it would allow the mobility of vaccinated horses. Thus, economical losses associated with this disease could be avoided.

Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus

Overlapping fragments of the outermost capsid protein VP2 of African horse sickness virus serotype 4 (AHSV-4) have been expressed in Escherichia coli. Horse sera from infected and vaccinated animals, rabbit sera, and mice monoclonal antibodies specific for AHSV were used to screen these fragments for antigenic regions. The screening revealed that the major antigenic domain of the AHSV-4 VP2 is localized in a central region (amino acids 200 to 413) and that both the N-terminal region (aa 1-159) and the half C-terminal region (aa 414-1060) are not immunogenic. All the fragments containing a region between amino acids 253 and 413 (fragment H) were able to elicit consistently high titers of neutralizing antibodies. The ability of several subfragments of this region to evoke neutralizing antibodies indicates the presence of several sites inside this domain. However, neutralizing antibodies in sera of horse infected or vaccinated with attenuated viruses were not absorbed by fragment H, indicating that this domain is not immunodominant in AHSV. This information might be useful in designing a subunit vaccine against AHSV infection.

Diagnosis of African horsesickness

African horsesickness (AHS) is a very serious, non-contagious disease of horses and other solipeds caused by an arthropod-borne orbivirus of the family Reoviridae. The epizootic nature of the disease makes rapid, accurate diagnosis of AHS absolutely essential. Currently, diagnosis of AHS is based on typical clinical signs and lesions, a history consistent with vector transmission and confirmation by laboratory detection of virus and/or anti-AHS virus antibodies. The clinicopathologic presentation of AHS, current and next generation laboratory diagnostic methods are discussed.

Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization

African horsesickness virus (AHSV) is a gnat-transmitted member of the Orbivirus genus of the Reoviridae family. The virus has a genome of 10 double-stranded RNA species (L1-L3, M4-M6, S7-S10). The L2 and M6 genes of AHSV serotype 4 (AHSV-4) which encode the outer capsid proteins VP2 and VP5, respectively, were inserted into recombinant baculoviruses downstream of the baculovirus polyhedrin, or p10 promoters. Recombinant baculoviruses expressing VP2, VP5, or VP2 and VP5 proteins of AHSV-4 were isolated. The expressed AHSV proteins were similar in size and antigenic properties to those of viral AHSV-4. Expressed VP2 and VP5 proteins were purified to homogeneity and utilized to differentiate sera from vaccinated and infected horses. Antigens were also used to determine whether any other AHSV serotypes are related to AHSV-4. The results indicated that AHSV-4 is distantly related to some serotypes (e.g., AHSV-2, -6, and -9) but not to others (e.g., AHSV-5 and -7). Hyperimmune monospecific antisera raised in rabbits with purified VP2 neutralized the infectivity of a virulent strain of AHSV-4 isolated from an infected horse during a recent outbreak of the disease in Spain.

Baculovirus expression of non-structural protein NS2 and core protein VP7 of African horsesickness virus serotype 3 and their use as antigens in an indirect ELISA

Non-structural protein NS2 and core protein VP7 of African horsesickness virus serotype 3 (AHSV3) were expressed in Spodoptera frugiperda cells by recombinant baculoviruses containing the relevant genes. These proteins were purified and analysed by polyacrylamide gel electrophoresis and Western blot. NS2 and VP7 were used separately as antigens in an indirect ELISA for the detection of AHSV antibodies. Both antigens cross-reacted with hyperimmune guinea-pig antisera to infected cell lysates of all nine known AHSV serotypes and to antisera obtained from horses immunized with attenuated virus of seven AHSV serotypes.

Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine

The immunity induced by two inoculations of a commercial inactivated African horse sickness (AHS) serotype 4 (AHSV-4) vaccine was studied. No adverse reaction was observed in five horses following vaccination. Following challenge-inoculation, no clinical signs attributable to AHS, no viraemia indicating infection, and no anamnestic response was observed in the vaccinated ponies. Two control ponies developed clinical signs typical of AHS, high levels of viraemia, and died 7 and 8 days postchallenge-inoculation. The quality of immunity induced by the two-dose regimen was compared with a one-dose regimen from a previous study; in the one-dose study following challenge-inoculation, six of nine ponies were protected from clinical signs of AHS, seven of the nine vaccinated ponies developed an anamnestic response, and one pony had a viraemia about 10(3) 50% mouse lethal dose of AHSV-4 per ml of blood for 3 days following challenge-inoculation. The utility of an efficacious inactivated AHS vaccine in the control and eradication of AHS from a non-endemic area is discussed. The lack of viraemia following vaccination with an inactivated vaccine and the prevention of vector infection by animals exposed to field virus are important in the eradication of AHS.

The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA

A full-length cDNA clone of genome segment 7 of African Horse Sickness Virus, serotype 9 (AHSV9) was obtained using the PCR technique. The clone was sequenced and found to be 98.27% homologous to the previously published sequence of the equivalent cDNA clone from AHSV4 at the nucleotide level and to exhibit 99.7% identity at the amino acid level. The cDNA clone was transferred to pGEX-2T (Pharmacia), a bacterial expression vector, such that the reading frame of AHSV9 VP7 was continuous with that of the bacterial glutathione-S-transferase (GST) protein, under the control of the bacterial tac promoter. On induction with IPTG a fusion protein consisting of GST and VP7 was synthesised, which was readily purified on a GST-sepharose column (Pharmacia). The fusion protein reacted equally well in an indirect ELISA using monoclonal antibodies specific for AHSV9 VP7 or polyclonal guinea pig antisera raised against AHSV9 infectious sub-viral particles. This protein was also shown to be a suitable substitute for virus antigen, prepared from infected BHK cell extracts, in a competitive ELISA. Antibodies titres recorded for AHSV9 positive and negative horse sera were similar in the competitive ELISA using either bacterial AHSV VP7 or BHK extracted virus as the source of antigen, in combination with monoclonal or polyclonal antibodies, respectively, as the detectors.

Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2

A panel of monoclonal antibodies (MAbs) was generated against African horsesickness virus serotype 4 (AHSV/4). Three of the MAbs (SA6, OH3, and ME11) strongly neutralized the homologous virus and a heterologous type 4 isolate. The MAbs did not cross-neutralize AHS serotypes 1-3 or 5-9. The MAbs immunoprecipitated a viral protein of 108 kDa which co-migrated with VP2. Pretreatment with SA6 prevented mortality of 71% of day-old mice after intracranial injection of 100 LD50 of AHSV/4, while OH3 and ME11 significantly increased the average survival time of challenged animals. This study demonstrates that neutralizing epitope(s) for AHS are located on VP2 and that antibodies to these epitope(s) are protective in a neonatal mouse model.

Isolation and identification of African horse sickness virus during an outbreak in Lagos, Nigeria

An outbreak of African horse sickness involving two horse stables in Lagos, Nigeria, was investigated. Inoculation of blood from infected horses into suckling albino mice resulted in isolation of a virus which was identified as African horse sickness virus by the complement fixation test. The clinical, pathological and epizootiological findings (reported elsewhere) were consistent with African horse sickness. Potential threats of the epidemic to international horse trade are briefly highlighted.

Seroepidemiological study of African horse sickness virus in The Gambia

An indirect enzyme-linked immunosorbent assay was used for the screening of horse sera from The Gambia for antibodies against African horse sickness virus (AHSV). The AHSV antigen used for coating was semipurified according to the method of Manning and Chen (Curr. Microbiol. 4:381, 1980); control mock-infected Vero cell antigen was treated in the same manner. A total of 459 horse serum samples were assayed at a single dilution (1:10), and their reactivities were compared with those of reference positive anti-AHSV and reference negative horse sera. A total of 81% of the horse serum samples clearly contained antibodies against AHSV; this consisted of 18% (of the total number of serum samples) strongly positive, 46.5% moderately positive, and 16.5% weakly but still clearly positive. Such results suggest a high prevalence of AHSV in the regions from whence the samples originated. Reports from investigations in other countries in this area of West Africa have also shown a high prevalence for anti-AHSV antibodies in equids. The question is raised as to how the animals became seropositive and whether the observations represent an increased resistance of horses living in a region in which AHS is enzootic.

Circulation of African horsesickness virus in zebra (Equus burchelli) in the Kruger National Park, South Africa, as measured by the prevalence of type specific antibodies

In the Kruger National Park 75% of zebra foals are born in October-March and they lose their passive immunity against African horsesickness virus (AHSV) when they are 5-6 months old. One month later infection with different serotypes of AHSV amounts to 31% and thereafter infections increase rapidly to almost 100% before the foals are 12 months old. The capability of zebra to maintain AHSV is clearly illustrated by the continuing infections during every month of the year with a peak period in winter. This peak is ascribed to the presence of large numbers of susceptible foals in the presence of active Culicoides species.

Rapid generation of monoclonal antibody-secreting hybridomas against African horse sickness virus by in vitro immunization and the fusion/cloning technique

Splenocytes from non-immune mice were stimulated in vitro using an equimolar mixture of factors from mixed lymphocyte reaction (MLR) and from phorbol-12-myristate 13-acetate (PMA) stimulated EL-4 cells, and concomitantly immunized with inactivated African horse sickness virus (AHSV) antigen serotype 4 or viral proteins 2 and 5 from AHSV serotype 9. Fusion with NSO myeloma cells was performed five days after primary or secondary stimulation/immunization. The record of hybridoma growth after a standard method of fusion, expansion of cells and subsequent cloning was compared with a fusion/cloning method in which cells were cloned within 2 to 3 days of the fusion event. Detection of antigen specific antibodies in the hybridoma culture supernatants was successful only with cells derived from primary stimulation/immunizations. Antibodies were detected using an indirect ELISA with the immunizing antigen coated on to the surface of the plates. Monoclonal hybridomas were isolated within 2 to 3 weeks using the fusion/cloning method, compared with the standard method, where it took 4 to 5 weeks. Although the total number of clones isolated from the fusion/cloning method was less than that obtained through the standard method, the yield of specific antibody-producing hybridomas as a percentage of the total picked was often more efficient with the fusion/cloning method. With respect to the immunoglobulin isotype produced, not all of the antibodies could be classified by the ELISA system used; 14% of anti-AHSV positive clones were identified as IgG-secreting cells, 25% as IgM-secreting, 18% were cross-reacting with IgG and IgM, and 43% could not be classified. Similar results in all aspects of the work were obtained whether a crude infected cell extract or purified outer capsid polypeptides VP2/5, from serotype 4 and serotype 9 respectively, were used.

Group-reactive ELISAs for detecting antibodies to African horsesickness and equine encephalosis viruses in horse, donkey, and zebra sera

Group-reactive enzyme-linked immunosorbent assays (ELISAs) were developed to selectively detect antibodies to African horsesickness virus (AHSV) and equine encephalosis virus (EEV), 2 orbiviruses that infect equids. In indirect ELISA, guinea pig antisera to all known AHSV or EEV serotypes recognized immobilized AHSV serotype 3 or EEV Cascara, respectively. Antisera from naturally infected animals did not cross-react with their respective heterologous viruses. The ELISA was used in parallel with the complement fixation (CF) and agar gel immunodiffusion tests to detect antibodies in sera from animals in the field. The ELISA distinguished among those that contained antibodies to AHSV, EEV, or both viruses and was useful with sera that did not yield results in CF tests because of anticomplementary activity. Zebra and donkeys, both potential subclinical carrier animals in Africa, contained AHSV or EEV antibodies. Some sera reacted with 1 of the 2 orbiviruses, whereas others reacted with both. The ELISA can be used in projected epidemiological studies in which many serum samples must be assayed.

Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and non-structural proteins

A panel of 32 hybridoma cell lines secreting monoclonal antibodies (MAbs) reactive with African horsesickness virus serotype 4 (AHSV-4) has been developed. Four of the MAbs recognized the major core antigen VP7, twenty recognized the outer capsid protein VP2 and eight reacted with the non-structural protein NS1. With the VP7-specific MAbs a rapid and sensitive double antibody sandwich immunoassay has been developed to detect viral antigen in infected Vero cells and in spleen tissue from AHSV-infected horses. The sensitivity of the assay is 10 ng viral antigen per 100 microliters. The NS1-specific MAbs allowed visualization by immunofluorescence of tubule-like structures in the cytoplasm of infected Vero cells. This can be very useful as a confirmatory diagnostic procedure. The antigenic map of the outer capsid VP2 protein with MAbs is also reported.

Production and properties of monoclonal antibodies against African horsesickness virus, serotype 3

Four polyethylene glycol-mediated cell fusions yielded a total of 23 monoclonal antibodies (McAbs) specific for African horsesickness virus (AHSV). Two recognised the major core structural polypeptide, VP7, while one each was specific for the outer capsid proteins, VP2 and VP5. The remainder co-precipitated both VP2 and VP7. An inhibition ELISA and radio-immunoprecipitation revealed two types of co-precipitating McAbs, distinguishable from each other by the different relative amounts of the two proteins they precipitated. Only co-precipitating McAbs reduced the size and number of plaques formed by AHSV on VERO cell monolayers, but even at low dilution did not completely abolish virus infectivity. A McAb specific for VP7 showed potential as a group-reactive diagnostic reagent since guinea pig antisera to all nine serotypes of AHSV, as well as an anti-serotype 4 horse serum and an anti-serotype 3 rabbit serum, inhibited its binding in ELISA to AHSV serotype 3.

Encephalitis and chorioretinitis associated with neurotropic African horsesickness virus infection in laboratory workers. Part III. Virological and serological investigations

Four cases of encephalitis with chorioretinitis occurred in the vaccine-packing section of a veterinary research institute: 1 in 1982, 1 in 1985 and 2 in 1989. No viruses were isolated from patients and serological tests failed to reveal significant antibodies to a range of viruses incorporated in veterinary vaccines or to other likely pathogens, except for low titres of complement-fixing antibody to African horsesickness (AHS) virus in all 4 patients. In confirmatory tests, high enzyme immunoassay titres of antibody to AHS virus occurred in the 4 patients and lower titres in 5/58 other workers at the institute. The 4 patients had significant plaque reduction neutralisation antibody titres to some of the strains of virus incorporated in AHS vaccine, particularly to serotypes 1 and 6, which had undergone neuro-adaptation through serial intracerebral passage in mice and which were known to be encephalitogenic following intranasal instillation in horses, guinea pigs and dogs. It is believed that the patients may have acquired aerosol infection with AHS virus as a result of accidental breakage of freeze-dried vaccine bottles.

An attempt to define the host range for African horse sickness virus (Orbivirus, Reoviridae) in east Africa, by a serological survey in some Equidae, Camelidae, Loxodontidae and Carnivore

A survey was carried out in horse, zebra, elephant, camel, sheep and goat and wild carnivore sera for virus-serum neutralising antibody to the nine type strains of African horse sickness virus. Antibody was found amongst the horse, zebra and elephant sera to all nine different strains. No antibody was detected in any sera from camels, sheep and goats. None was found in sera from hyaena and jackals in this series but had been detected earlier.

Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent

The major core protein, VP7, of African horsesickness virus serotype 4 (AHSV-4), the aetiological agent of a recent outbreak of the disease in southern Europe, was expressed in insect cells infected with a recombinant baculovirus containing a cloned copy of the relevant AHSV gene (S7). Analyses of its biochemical and antigenic properties confirmed the authenticity of the protein expressed. The high-level expression of VP7 under the control of the strong polyhedrin promoter of Autographa californica nuclear polyhedrosis virus induced disc-shaped crystals in infected insect cells. This enabled us to purify the protein by a one-step ultracentrifugation procedure and to utilize it for the detection of antibodies raised in horses to various serotypes of AHSV. A serological relationship between AHSV and two other orbiviruses, bluetongue virus and epizootic haemorrhagic disease virus, was also demonstrated.

The detection of African horse sickness virus antigens and antibodies in young Equidae

Four ponies were each inoculated with a different serotype of African horse sickness virus (AHSV) which had been passaged through cell culture in order to achieve attenuation. Three of the ponies died suddenly after showing mild clinical signs, the fourth pony remained clinically normal and was killed at day 38. Infectious AHSV was isolated from blood samples collected at intervals from all four ponies. Positive antigen ELISA reactions were only observed with blood samples from two of the ponies on the two days preceding death. Specific AHSV antibodies were detected by ELISA in serum samples from the other two ponies although one eventually died. African horse sickness viral antigens were detected by ELISA in post-mortem tissue samples collected from all four ponies. No infectious virus could be detected in tissue samples taken post-mortem from the pony which survived African horse sickness (AHS) infection. In the event of a suspected outbreak of AHS it is recommended that sera and heparinized blood should be tested for specific antibodies and AHSV antigen respectively. When available, post-mortem tissues, including spleen, heart, lung and liver, should also be tested for AHSV antigen. Although the ELISA used for the detection of AHSV antigen is highly sensitive and specific, negative ELISA results should be confirmed by virus isolation attempts.

The use of ELISA for the detection of African horse sickness viruses in Culicoides midges

The use of ELISA for the detection of African horse sickness viruses (AHSV) in midges preserved in 5.0% formalin was evaluated. No differences were detected by ELISA when testing AHSV infected batches of Culicoides midges collected in diluent with or without the addition of formalin. The ELISA was considered highly sensitive and easily distinguished between non-infected midges and batches containing varying numbers of infected and non-infected midges. Positive ELISA reactions were detected with formalin-preserved midges collected from the south of Spain during the 1988 AHSV epizootic. The assay, therefore, may be used in surveillance studies of either fresh or formalin-preserved midges to identify undisclosed and persistent AHSV foci. This information would be useful in helping to eradicate the virus from Europe and North Africa.

Antibodies in horses, mules and donkeys following monovalent vaccination against African horse sickness

A total of 256 sera collected from three species of domesticated equidae in four different Spanish provinces were examined 1-4 months after the administration of attenuated monovalent African horse sickness virus (AHSV) serotype 4 vaccine. Approximately 10% of the sera were negative by ELISA, virus neutralization, agar gel immuno-diffusion and complement fixation tests. Similar negative reactions were recorded with sera from two ponies after experimental primary vaccination. The rapid rise in antibodies in sera from these two ponies, after a second dose of vaccine, suggested they would probably have been immune to challenge. It is therefore suggested that the apparent absence of antibodies against AHSV in some animals after primary vaccination may not necessarily indicate a total lack of protection.

Laboratory confirmation of African horsesickness in the western Cape: application of a F(ab')2-based indirect ELISA

Recently a suspected outbreak of African horsesickness in the Western Cape Province resulted in the deaths of four foals and one adult horse. Spleen samples from these animals were subjected to analysis by an enzyme-linked immunosorbent assay (ELISA) which uses F(ab')2 fragments of immunoglobulins to detect African horse sickness virus (AHSV) antigens. The results of the immunoassay were compared with those obtained by isolation followed by serotyping as is currently applied by the Reference Centre at the Veterinary Research Institute, Onderstepoort. Samples of spleen tissue from the four foals contained sufficient antigen to be readily detectable by ELISA. A marginally positive signal was obtained with the tissue from the adult horse. This sample was inoculated onto VERO cells and four days were allowed for viral multiplication. Subsequently, when the cell culture was assayed by F(ab')2-ELISA, a much higher absorbance value than that obtained with the original spleen sample resulted, thus confirming the presence of AHSV in the initial specimen. The F(ab')2-ELISA has potential to be used as an initial diagnostic test to screen for AHSV.

A serogroup specific enzyme-linked immunosorbent assay for the detection and identification of African horse sickness viruses

A serogroup specific, indirect, sandwich ELISA was developed for the rapid detection of African horse sickness virus and viral antigens in field samples or in infected tissue cultures. The assay was shown to be highly sensitive and capable of providing confirmation of clinical diagnosis within one day. The results demonstrated that this ELISA will be useful for epidemiological surveillance of insect and mammalian host populations.

Purification and characterization of the major group-specific core antigen VP7 of bluetongue virus synthesized by a recombinant baculovirus

The major core protein, VP7, of bluetongue virus serotype 10 (BTV-10) has been purified from insect cells infected with a genetically manipulated recombinant baculovirus. The high level expression of VP7 (in excess of 100 mg per litre of culture) and its presence in the soluble fraction of infected cells following lysis by detergent has allowed the purification of the protein virtually to homogeneity (95%) by a simple two-step procedure of ammonium sulphate fractionation and ion-exchange chromatography. The purified antigen is highly immunogenic and has been shown in an ELISA to be reactive with antisera of 24 BTV serotypes (1 to 24) as well as with an antiserum raised to African horsesickness virus type 4 (AHSV-4), a representative of another serogroup of orbiviruses. In confirmation of these data a monospecific antiserum raised with the expressed product has been shown by Western blot analyses to react with other BTV serotypes as well as with two serotypes of epizootic haemorrhagic disease virus (EHDV-1 and EHDV-2), a closely related orbivirus. The data indicated that VP7 is a highly conserved protein amongst BTV serotypes and at least partly conserved amongst three serogroups of orbiviruses.

An indirect sandwich ELISA utilising F(ab')2 fragments for the detection of African horsesickness virus

African horsesickness virus (AHSV), an important disease of equines is caused by an orbivirus. Because of the need to contain the spread of the disease, it is often essential to make a rapid diagnosis. For this purpose, an ELISA capable of detecting viral antigen in animal tissue and in cell culture fluid was developed. Immobilised F(ab')2 fragments prepared by digestion of AHSV-specific IgG with pepsin were used to trap virus from tissue homogenates or cell culture supernatant. After addition of intact IgG as detecting antibody, Staphylococcus aureus protein A labelled with horseradish peroxidase was added to allow visualisation of the reaction. Polyclonal antibodies directed against either whole AHSV or viral core particles were suitable as detecting antibodies. On the other hand, a monoclonal antibody that was specific for a major core protein, VP7, gave a much weaker signal in the ELISA. All known AHSV serotypes were recognised in the F(ab')2-ELISA by polyclonal antisera against either whole virus particles or viral cores. Immunoprecipitation of AHSV structural polypeptides showed that such antisera contained populations of antibodies directed against core proteins. The F(ab')2-ELISA has potential as a diagnostic technique for AHSV infections.

A competitive ELISA for the detection of group-specific antibodies to African horse sickness virus

A competition enzyme-linked immunosorbent assay (ELISA) has been developed for the rapid identification and quantification of antibodies against African horse sickness (AHS) in sera from solipeds. The data showed the ELISA to be sensitive, specific and reliable. More than 1600 sera from 37 different countries were examined and results compared with those obtained by agar gel immuno-diffusion (AGID) tests. In no case did any of 775 sera from countries where AHS has never been reported and where AHS vaccines are not used, record an ELISA titre greater than 4. A titre equal to or greater than 8 was considered positive. Using this criterion, 96.3% of sera tested in both assays were in agreement. Doubtful results by AGID (1.7%) were clearly defined in terms of positivity and negativity by ELISA. This ELISA is suited for the rapid laboratory confirmation of AHS and should be considered as a replacement for the traditional AGID test.

Laboratory diagnosis of African horse sickness: comparison of serological techniques and evaluation of storage methods of samples for virus isolation

Five serological methods of diagnosing African horse sickness were evaluated, using a battery of serum samples from experimental horses vaccinated and challenged with each serotype of African horse sickness virus (AHSV1 through AHSV9): agar gel immunodiffusion (AGID), indirect fluorescent antibody (IFA), complement fixation (CF), virus neutralization (VN), and enzyme-linked immunosorbent assay (ELISA). The 5 tests were also compared using a panel of field samples, convalescent equine sera with antibodies to domestic equine viral diseases, and sera from horses awaiting export. The ELISA described in this paper was group specific. It did not require calibration with a standard positive serum but did yield elevated values with negative sera that were repeatedly frozen and thawed or heat inactivated. The IFA test was sensitive but could not be used on some field sera as the control cells exhibited fluorescence, possibly due to the animal being recently vaccinated with cell culture material. Sixty-two experimental sera were compared by VN, CF, AGID, and ELISA. Forty sera, 10 positive and 30 negative, were correctly classified by the 5 serologic assays. The 22 remaining sera gave mixed reactions. The AGID had no false positive results but had false negative results for up to 20% of the samples, depending upon the comparison. The VN, CF, and ELISA were similar in their variability. The length of time that virus could be recovered from a viremic blood sample was compared in an evaluation of storage methods for virus isolation samples. Washed erythrocytes were held at 4 C, washed erythrocytes plus stabilizer were held at -70 C, and blood that was drawn into a preservative (oxalate/phenol/glycerol) was held at 4 C.(ABSTRACT TRUNCATED AT 250 WORDS)

Observations on antibody levels associated with active and passive immunity to African horse sickness

Tests for neutralising (NT) antibodies to the nine serotypes of African horse sickness (AHS) virus on the sera of three groups of horses confirmed that an increasing number of immunisations with vaccine containing attenuated strains of serotypes 1 to 6 of the virus, leads to broader response to the various serotypes and to higher individual titres. Nevertheless some horses failed to respond to one or more serotypes despite receiving numerous immunisations and it was clear that vaccine containing only serotypes 1 to 6 could not be relied upon to induce adequate cross-immunity to serotypes 7 to 9 of the virus. Highest antibody titres and broadest cross-reactivity were recorded in a fourth group of horses which had apparently suffered natural infection recently. The levels of antibody acquired from colostrum by seven foals generally correlated well with the levels of antibody in the sera of their dams and the rate of decline of passively acquired antibody was proportional to initial titre. Antibodies to individual serotypes of virus declined to undetectable levels in two to four months from birth in some instances implying that susceptibility to infection could occur well before the age of six to nine months which is commonly recommended for initial immunisation. Vaccination of eight foals at three to four months of age resulted in weak antibody response but did not adversely affect pre-existing low levels of maternal antibody so that early immunisation could be recommended as a means for attempting to control the losses of foals experienced in Zimbabwe.

African horse sickness in Zimbabwe: 1972 to 1981

During the nine years from October 1972 to September 1981 African horse sickness (AHS) virus was isolated from 23 suspected cases of the disease in Zimbabwe and complement fixation antibody titres indicative of recent infection were detected in a further 49 horses. The 23 isolations belonged to seven of the nine known serotypes of AHS virus. In response to a questionnaire in 1980 the owners of 20% (1,654/8,000) of the horses in Zimbabwe indicated that they had recorded 207 cases of clinically diagnosed AHS with 107 deaths from 1975 to 1980. Fifty-six cases with 50 deaths had occurred in foals and many of the other cases occurred in horses which had been vaccinated. It was concluded that the immunity induced by vaccine and maternal immunity warranted further investigation.

A single dilution enzyme-linked immunosorbent assay for the quantitative detection of antibodies to African horsesickness virus

A single dilution enzyme-linked immunosorbent assay (ELISA), utilizing a reference serum with a known, predetermined end-titre was used to compute antibody titres of serum samples against African horsesickness virus. Compared to the complement fixation test it was found to be highly reproducible and sensitive. The assay also reduced the effect of between-test variations on test results and proved superior to an existing single-dilution ELISA method.

Isolation and identification of African horsesickness virus from naturally infected dogs in Upper Egypt

African horsesickness virus was isolated from blood samples of street dogs in Aswan Province in Arab Republic of Egypt. Of six isolated "dog strain" African horsesickness viruses, three viruses designated D2, D6 and D10 have been identified as type 9 African horsesickness virus. Methods of isolation, tissue culture adaptation, serological indentification and typing are described. Horses experimentally infected with dog viruses showed febrile reaction and characteristic clinical and pathological signs of African horsesickness. Reisolation of African horsesickness virus type 9 was achieved from the horses during serial passages.

Inactivation of African horse-sickness virus by betapropiolactone and by pH

The inactivation of several types of African horse sickness virus (AHSV) by pH and by betapropiolactone (BPL) was studied. At 19 degrees - 22 degrees C the virus was stable between pH 6.0 and 10.4, whether suspended in mouse brain or in serumfree buffer. Below pH 5.6 and above pH 10.9, more than 99 per cent of infectivity was inactivated within 15 minutes. The addition of 50 per cent serum did not influence pH stability. Disinfection in the presence of citric acid and caustic soda is briefly discussed. Inactivation by BPL was complete within 30 minutes at 37 degrees C, yet incomplete after 15 hours at 4 degrees C. Types 3 and 9 virus grown in suckling mouse brain and types 1, 3 and 9 produced in pig kidney cells were equally susceptible to 0.1 per cent BPL, more than 99.9 per cent being inactivated. The effectiveness of BPL was reduced at least 10-fold by the addition of 50 per cent serum. No infective virus was detected following incubation of either tissue culture virus with 0.2 per cent BPL or of mouse brain virus with 0.3 per cent BPL. Virus suspensions exposed to 0.3 per cent BPL required buffering with Tris of at least 0.05 molar strength in order to maintain the pH within an acceptable range. Inactivated antigens prepared with 0.4 per cent or lower concentrations of BPL were immunogenic in guinea pigs.